We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 0A5R market cap is 0. The company's latest EPS is SEK -6.9196 and P/E is -1.09.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Revenue | 0 | 184.83M | 874k | 229.35M | 805.74M |
| Operating Income | -133.2M | -27.88M | -382.22M | -518.37M | -398.87M |
| Net Income | -132.05M | -32.58M | -433.49M | -500.29M | -412.27M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Assets | 648.42M | 845.2M | 1.51B | 1.46B | 1.95B |
| Total Liabilities | 30.24M | 57.13M | 250.15M | 451.63M | 1.19B |
| Total Equity | 618.18M | 788.07M | 1.26B | 1.01B | 766.26M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Operating | -128.19M | -71.01M | -309.18M | -461.59M | -311.35M |
| Investing | N/A | -18.07M | -172.61M | -24.34M | -5.14M |
| Financing | 716.57M | 198.84M | 768.56M | 435.16M | 575.99M |
| Market Cap | 0 |
| Price to Earnings Ratio | -1.09 |
| Price to Sales Ratio | 0.56 |
| Price to Cash Ratio | 0.36 |
| Price to Book Ratio | 0.59 |
| Dividend Yield | - |
| Shares Outstanding | 59.58M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Calliditas Therapeutics Ab |
| Address |
kungsbron 1, c8 stockholm SE-111 22 |
| Website | https://www.calliditas.se |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
